Recommended Resources
June 11, 2009
Bookshelf
March 24, 2005 – Kathy LaTour
Letters from our Readers
March 24, 2005
Message from the Editor-at-Large
March 24, 2005 – Kathy LaTour
v4n1 - A Sweet Idea
March 24, 2005 – Kathy LaTour
v4n1 - Tips to Prevent Bleeding
March 24, 2005 – Debra Wood, RN
v4n1 - Giving Platelets
March 24, 2005
v4n1 - Megakaryocytes & Platelet Production
March 24, 2005 – Susan R. Peck, PhD
v4n1 - Is There a Link to Hodgkin's Disease?
March 24, 2005 – Susan R. Peck, PhD
v4n1 - Is It Really Hodgkin's Disease?
March 24, 2005 – Susan R. Peck, PhD
Society For Integrative Oncology
March 24, 2005 – Kathy LaTour
Integrative Modalities
March 24, 2005 – Kathy LaTour
The Science Behind Integrative Medicine
March 24, 2005 – Kathy LaTour
Esophagitis: A Common Radiation Side Effect
March 24, 2005 – Carol L. Kornmehl, MD
Risk Factors
March 24, 2005 – Amy D'Orazio, PhD
A Confusing Array of Choices
March 24, 2005 – Jennifer M. Gangloff
What To Know Before You Go
March 24, 2005 – Jennifer M. Gangloff
Choosing a Qualified Practitioner
March 24, 2005 – Jennifer M. Gangloff
Navigating the Caregiver Terrain
March 24, 2005 – Marc Silver
The Science & Controversy Behind Touch Therapies
March 24, 2005 – Jennifer M. Gangloff
The Healing Journey
March 24, 2005 – Kathy LaTour
Esophageal Cancer: A Disease on the Rise
June 27, 2005 – Rabiya S. Tuma, PhD
Recommended Resources
June 11, 2009
Bookshelf
March 24, 2005 – Kathy LaTour
Letters from our Readers
March 24, 2005
Message from the Editor-at-Large
March 24, 2005 – Kathy LaTour
v4n1 - A Sweet Idea
March 24, 2005 – Kathy LaTour
v4n1 - Tips to Prevent Bleeding
March 24, 2005 – Debra Wood, RN
v4n1 - Giving Platelets
March 24, 2005
Currently Viewing
v4n1 - Megakaryocytes & Platelet Production
March 24, 2005 – Susan R. Peck, PhD
v4n1 - Is It Really Hodgkin's Disease?
March 24, 2005 – Susan R. Peck, PhD
Society For Integrative Oncology
March 24, 2005 – Kathy LaTour
Integrative Modalities
March 24, 2005 – Kathy LaTour
The Science Behind Integrative Medicine
March 24, 2005 – Kathy LaTour
Esophagitis: A Common Radiation Side Effect
March 24, 2005 – Carol L. Kornmehl, MD
Risk Factors
March 24, 2005 – Amy D'Orazio, PhD
A Confusing Array of Choices
March 24, 2005 – Jennifer M. Gangloff
What To Know Before You Go
March 24, 2005 – Jennifer M. Gangloff
Choosing a Qualified Practitioner
March 24, 2005 – Jennifer M. Gangloff
Navigating the Caregiver Terrain
March 24, 2005 – Marc Silver
The Science & Controversy Behind Touch Therapies
March 24, 2005 – Jennifer M. Gangloff
The Healing Journey
March 24, 2005 – Kathy LaTour
Esophageal Cancer: A Disease on the Rise
June 27, 2005 – Rabiya S. Tuma, PhD
GERD: An Increasing Problem
March 24, 2005 – Elizabeth Whittington

v4n1 - Megakaryocytes & Platelet Production

BY Susan R. Peck, PhD
PUBLISHED March 24, 2005

Megakaryocytes are the parent cells that make platelets—sticky bodies that circulate in the bloodstream and help the blood to clot when you get cut. They are also the culprits that contribute to clot formation inside arteries and blood vessels, which can lead to strokes or heart attacks.

A single megakaryocyte can make between 1,000 and 3,000 platelets during its life span. Platelets are pinched off or shed from the parental megakaryocte and are made up of pieces of the megakaryocyte’s membrane. They contain granules with clotting factors and other proteins inside. Normally, there are about 150,000 to 400,000 platelets in every microliter of blood, and while this number can vary between people, it usually stays the same in a particular person throughout a lifetime, unless platelet production is disturbed. If the body suddenly has a higher need for platelets, the megakaryocytes in the bone marrow respond by dividing, increasing in size and producing more platelets.


Many types of chemotherapy can kill megakaryocytes, and it takes them time to regenerate. This can lead to a condition called thrombocytopenia, and, if left uncorrected, can lead to problems with bleeding and clotting. Usually, though not always, the numbers of megakaryocytes will eventually rebound after chemotherapy is stopped.

Not all forms of chemotherapy-related thrombocytopenia occur because the megakaryocytes have died. Velcade, one of the newer targeted agents, causes a transient drop in platelet counts without a corresponding drop in the number of megakaryocytes. This is because, although the megakaryocyte itself is left undisturbed, Velcade inhibits the platelets from budding off from the megakaryocyte. This process is reversed during the time between doses or once treatment has been completed.

Megakaryocytes need a protein called thrombopoietin (also known as megakaryocyte growth and development factor) in order to grow and
survive. This growth factor sends a signal to the megakaryocyte to divide and mature. For this reason, researchers are experimenting with synthetic forms of thrombopoietin to determine if this protein could help prevent chemotherapy-induced thrombocytopenia.

Studies in both animals and humans suggest synthetic forms can stimulate megakaryocyte development and platelet production, without notable side effects. In the future, this approach may be useful in protecting cancer patients from one of the more serious side effects of chemotherapy

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In